Despite advancements in dialysis technology, patients with kidney failure who are on maintenance haemodialysis (MHD) continue to experience high morbidity and mortality. Haemoadsorption combined with haemodialysis (HAHD) has emerged as a promising therapy to address these challenges. In light of the increasing adoption of HAHD in patients receiving MHD, there is a pressing need to demonstrate the safety and effectiveness of HAHD treatment. Consequently, a panel of Chinese experts developed a consensus on HAHD on the basis of the published literature and collective clinical experience. The consensus outlines six critical issues concerning HAHD treatment: patient population, contraindications, heparinization and priming procedures, prescription of HAHD, adjustment of medication dosages, and potential treatment-associated adverse events. After evaluation using a Delphi methodology, 19 statements achieved consensus (7 recommendations and 12 practice points). The overarching goal is to provide best-practice recommendations formulated by the HAHD Consensus Group to guide the use of haemoadsorption in MHD patients.
Gan et al. (Sat,) studied this question.